Prognostic of Core Binding Factor (CBF) Acute Myeloid Leukemia With Complex Karyotype
- 11 September 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (3), e199-e205
- https://doi.org/10.1016/j.clml.2021.09.007
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- The genomic landscape of core-binding factor acute myeloid leukemiasNature Genetics, 2016
- Comprehensive mutational profiling of core binding factor acute myeloid leukemiaBlood, 2016
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Complex karyotype, older age, and reduced first‐line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long‐term follow‐upAmerican Journal of Hematology, 2015
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trialsThe Lancet Oncology, 2014
- High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcomeLeukemia, 2014
- Prognosis of patients with core binding factor acute myeloid leukemia after first relapseHaematologica, 2013
- Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B StudyJournal of Clinical Oncology, 2005
- Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group studyBlood, 2000